189 related articles for article (PubMed ID: 30318876)
1. The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.
Plotti F; Scaletta G; Terranova C; Montera R; De Cicco Nardone C; Luvero D; Rossini G; Gatti A; Schirò T; Moncelli M; Guzzo F; Angioli R
Minerva Ginecol; 2019 Feb; 71(1):36-43. PubMed ID: 30318876
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
3. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis.
Lin J; Qin J; Sangvatanakul V
Eur J Obstet Gynecol Reprod Biol; 2013 Mar; 167(1):81-5. PubMed ID: 23228410
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
Simmons AR; Baggerly K; Bast RC
Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis.
Wu L; Dai ZY; Qian YH; Shi Y; Liu FJ; Yang C
Int J Gynecol Cancer; 2012 Sep; 22(7):1106-12. PubMed ID: 22854652
[TBL] [Abstract][Full Text] [Related]
6. Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.
Qu W; Li J; Duan P; Tang Z; Guo F; Chen H; Zhu X; Jiang SW
Expert Rev Mol Diagn; 2016 Dec; 16(12):1271-1282. PubMed ID: 27784171
[TBL] [Abstract][Full Text] [Related]
7. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.
Escudero JM; Auge JM; Filella X; Torne A; Pahisa J; Molina R
Clin Chem; 2011 Nov; 57(11):1534-44. PubMed ID: 21933899
[TBL] [Abstract][Full Text] [Related]
8. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis.
Chen Y; Ren YL; Li N; Yi XF; Wang HY
Eur Rev Med Pharmacol Sci; 2016 May; 20(10):1974-85. PubMed ID: 27249595
[TBL] [Abstract][Full Text] [Related]
9. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.
Capriglione S; Luvero D; Plotti F; Terranova C; Montera R; Scaletta G; Schirò T; Rossini G; Benedetti Panici P; Angioli R
Med Oncol; 2017 Aug; 34(9):164. PubMed ID: 28825178
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of HE4 for ovarian cancer: a meta-analysis.
Yu S; Yang HJ; Xie SQ; Bao YX
Clin Chem Lab Med; 2012 Feb; 50(8):1439-46. PubMed ID: 22868811
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
14. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.
Scaletta G; Plotti F; Luvero D; Capriglione S; Montera R; Miranda A; Lopez S; Terranova C; De Cicco Nardone C; Angioli R
Expert Rev Anticancer Ther; 2017 Sep; 17(9):827-839. PubMed ID: 28756722
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
16. Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers.
Li J; Chen H; Curcuru JR; Patel S; Johns TO; Patel D; Qian H; Jiang SW
Curr Drug Targets; 2017; 18(10):1158-1164. PubMed ID: 28382859
[TBL] [Abstract][Full Text] [Related]
17. Human epididymis protein 4 in endometrial cancer: A meta-analysis.
Li LM; Zhu YX; Zhong Y; Su T; Fan XM; Xi Q; Li MY; Fu J; Tan H; Liu S
Clin Chim Acta; 2018 Jul; 482():215-223. PubMed ID: 29630870
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis.
Bie Y; Zhang Z
World J Surg Oncol; 2014 May; 12():169. PubMed ID: 24885319
[TBL] [Abstract][Full Text] [Related]
19. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
20. HE4 in the differential diagnosis of ovarian masses.
Granato T; Porpora MG; Longo F; Angeloni A; Manganaro L; Anastasi E
Clin Chim Acta; 2015 Jun; 446():147-55. PubMed ID: 25892674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]